Journal: Journal of nanobiotechnology

Article Title: Evaluating the pro-survival potential of apoptotic bodies derived from 2D- and 3D- cultured adipose stem cells in ischaemic flaps.

doi: 10.1186/s12951-024-02533-1

Figure Lengend Snippet: Fig. 6 3D-ABs suppress oxidative stress and cell death, and stimulated angiogenesis in ischaemic flaps. (A) F-CHP staining for damaged collagen detec tion in the skin on POD7. Scale bars, 100 μm. (B) The three groups’ quantified F-CHP intensity (n = 6). (C) CD31 and α-SMA IF staining in the flap on POD7. Scale bars, 50 μm. (D) Quantified CD31/α-SMA-positive blood vessel density among the three groups (n = 6). (E) Dead cells in flap tissue sections on POD7 under the detection of TUNEL staining. Scale bar, 20 μm. (F) TUNEL-positive cell percentage in the dermal layer, quantified for each of the three groups (n = 6). (G) DHE staining of the skin tissues on POD7 among the three groups. Scale bars, 50 μm. (H) Quantified DHE among the three groups (n = 6). SEM error bars are used. Significance (*): p value < 0.05; equal variances ANOVA with LSD post hoc analysis or unequal variances Dunnett’s T3 technique

Article Snippet: The primary antibodies utilized were specific to CD31 (1:200), CD68 (1:200), α-SMA (1:200; Proteintech, 67735-1-Ig), iNOS (1:200), and Arg1 (1:200).

Techniques: Staining, TUNEL Assay

Journal: RSC Advances

Article Title: Thymoquinone protects against cardiac damage from doxorubicin-induced heart failure in Sprague-Dawley rats

doi: 10.1039/c8ra00975a

Figure Lengend Snippet: Fig. 4 Protein levels of TGF-b, Smad3, collagen I, collagen III, and a-SMA in cardiac tissue were determined by western blotting. Immunoblotting for TGF-b, Smad3, collagen I, collagen III, and a-SMA in cardiac tissues. Bar graph showing quantification of TGF-b, Smad3, collagen I, collagen III, and a-SMA protein expression. Data are given as the mean SEM; n ¼ 3 in each group. *p < 0.05 vs. DOX group.

Article Snippet: Primary antibodies against TGF-b (rabbit anti-TGF-b antibody, 1 : 1000; Proteintech, Wuhan, China), Smad3 (rabbit anti-Smad antibody, 1 : 1000; Proteintech), collagen I (rabbit anti-collagen I antibody, 1 : 1000; Proteintech), collagen III (rabbit anticollagen III antibody, 1 : 1000; Proteintech), a-SMA (rabbit anti-a-SMA antibody, 1 : 1000; Proteintech), P53 (rabbit antiP53 antibody, 1 : 1000; Proteintech), bcl-2(rabbit anti-bcl-2 antibody, 1 : 1000; Proteintech), anti-b-actin (1 : 1000; Cell Signaling Technology).

Techniques: Western Blot, Expressing

Journal: Acta Neuropathologica Communications

Article Title: C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation

doi: 10.1186/s40478-019-0755-x

Figure Lengend Snippet: The amino acid sequence of TDP-43 from N terminus (1) to C terminus (414). The highlighted regions are the peptides used to generate the polyclonal antibodies (MC2079, MC2085 and pTDP 409/410)

Article Snippet: In all 24 cases we performed serial sectioning and TDP-43 immunohistochemistry with four different TDP-43 antibodies: phosphorylated TDP-43 (pTDP-43) antibody (pS409/410, 1:5000 mouse monoclonal, Cosmo Bio Co., LTD) that recognizes TDP-43 with phosphorylated epitopes; anti TDP-43 antibody that recognizes a neoepitope in the C terminal fragment of cleaved TDP-43(cTDP-43) (MC2085, 1:2500 rabbit polyclonal, gift from Leonard Petrucelli, Mayo Clinic) [ ]; anti TDP-43 antibody that recognizes an epitope in the amino terminus (nTDP-43) (MC1079; 1:2500 rabbit polyclonal, gift from Leonard Petrucelli, Mayo Clinic) [ ] and a rabbit polyclonal anti-TDP-43 antibody (ProteinTech Group; Chicago IL; dilution 1:3000) which is a commercially available antibody.

Techniques: Sequencing